Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

400%(4 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

NCT03943290

terminatedphase_2

Clinical Trials (4)

Showing 4 of 4 trials

NCT03943290Phase 2

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Terminated

NCT02927080Phase 2

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated

NCT03124459Phase 2

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Terminated

NCT02257489Phase 1

Phase 1 Study of ACE-083 in Healthy Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4